Navigation Links
Gladstone founder receives American Heart Association Distinguished Scientist Award
Date:11/14/2011

SAN FRANCISCO, CANovember 15, 2011The American Heart Association will today present Gladstone Institutes Senior Investigator and President Emeritus Robert Mahley, MD, PhD, with the 2011 AHA Distinguished Scientist Award, bestowing yet another honor on one of Gladstone's founding cardiovascular scientists.

The Distinguished Scientist Award is the highest honor that the American Heart Association can give a scientist. Dr. Mahley is one of just five scientists this yearand the first from Gladstoneto receive the award. He will receive the award today during the annual AHA Scientific Sessions in Orlando, Fla.

Dr. Mahley, who founded Gladstone in 1979 before serving as its president for 30 years, is an internationally recognized expert on heart disease, cholesterol metabolism and, more recently, Alzheimer's disease. Early in his career, Dr. Mahley discovered the existence of apoE, a protein that transports cholesterol and helps to regulate cholesterol levels in the blood. After his arrival at Gladstone, he developed an understanding of the critical role that apoE plays in heart disease. This, in turn, laid the groundwork for the explosion of research related to apoE4, a detrimental type of apoE that is found in 1 in 4 Americans. Today, many scientists believe that apoE4 is linked to brain-cell injury and the progression of Alzheimer's disease, a devastating neurodegenerative disease that is the sixth leading cause of death in the United States.

"Dr. Mahley has long been an exemplar of excellence in cardiovascular research," said Dr. Garret FitzGerald, chair of the American Heart Association's Distinguished Scientists Selection Committee. "His penetrating insights and discoveries around apoE have shaped the field, influencing research in both cardiovascular biology and neurodegenerative disease. He is well deserving of this prestigious and exclusive award."

The American Heart Association, an organization that is committed to reducing the risk of heart disease and stroke, presents the AHA Distinguished Scientist Award to those who have had a significant and lasting impact on the fields of cardiovascular research and medicine. Previous recipients of the award include Nobel laureates Roger Tsien, PhD, of the University of California, San Diego and Martin Chalfie, PhD, from Columbia University.

"Dr. Mahley's life-long commitment to finding ways to prevent, treat and cure disease has been an inspiration to Gladstone scientists for decades," said R. Sanders Williams, MD, president of Gladstone. "We can think of no better choice for the AHA Distinguished Scientist Award than Gladstone's founding president."

Throughout his career, Dr. Mahley has championed the value of "basic" researchin which scientists focus on advancing our fundamental understanding of biologyto develop cutting-edge treatments that improve human health. He recently developed the Gladstone Center for Translational Research to facilitate the movement of aspects of Gladstone's basic research into therapies that can directly benefit patients. Dr. Mahleywho is also a professor of pathology and medicine at the University of California, San Francisco, with which Gladstone is affiliatedtoday continues to explore the exact role of apoE4 in Alzheimer's. Specifically, he is examining how apoE4 could be modified so as not to influence the progression of this deadly disease.

Several other preeminent organizations have also recognized Dr. Mahley for his contributions to science and medicine. For example, he has been elected to both the National Academy of Sciences and the Institute of Medicine, two of the highest honors available for U.S. scientists. He also recently received the Builders of Science Award from Research!America for his leadership at Gladstone, which he helped guide into one of the world's leading independent research institutes.


'/>"/>

Contact: Anne Holden
anne.holden@gladstone.ucsf.edu
415-734-2534
Gladstone Institutes
Source:Eurekalert  

Related biology news :

1. Gladstone scientists reveal that fat synthesizing enzyme is key to healthy skin and hair
2. Gladstone scientists reveal key enzyme in fat absorption
3. Gladstone scientists identify key factors in heart cell creation
4. Gladstones Shinya Yamanaka wins Lasker Award
5. Gladstone and Institute for Systems Biology collaborate on Huntingtons disease
6. Gladstones Shinya Yamanaka wins Kyoto prize
7. Gladstone scientists link hepatitis C virus infection to fat enzyme in liver cells
8. Gladstone scientists uncover mechanism for the major genetic risk factor of Alzheimers disease
9. Gladstone scientists identify genes involved in embryonic heart development
10. Gladstone to receive $5.6 million in federal funds to seek a cure for AIDS
11. Gladstone scientists offer new insight into the regulation of stem cells and cancer cells
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Gladstone founder receives American Heart Association Distinguished Scientist Award
(Date:5/24/2016)... , May 24, 2016 Ampronix facilitates superior patient care by providing unparalleled ... medical LCD display is the latest premium product recently added to the range of ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/16/2016)... , May 16, 2016   EyeLock LLC , ... announced the opening of an IoT Center of Excellence ... and expand the development of embedded iris biometric applications. ... level of convenience and security with unmatched biometric accuracy, ... identity aside from DNA. EyeLock,s platform uses video technology ...
(Date:5/9/2016)... May 9, 2016 Elevay is ... to expanding freedom for high net worth professionals seeking ... today,s globally connected world, there is still no substitute ... ever duplicate sealing your deal with a firm handshake. ... by taking advantage of citizenship via investment programs like ...
Breaking Biology News(10 mins):
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... services and solutions to the healthcare market. The company's primary focus is on ... sales and marketing strategies that are necessary to help companies efficiently bring their ...
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/23/2016)... , June 23, 2016   Boston ... of novel compounds designed to target cancer stemness ... has been granted Orphan Drug Designation from the ... treatment of gastric cancer, including gastroesophageal junction (GEJ) ... inhibitor designed to inhibit cancer stemness pathways by ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
Breaking Biology Technology: